{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:45:41Z","timestamp":1785415541648,"version":"3.56.0"},"reference-count":84,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_182003\/1"],"award-info":[{"award-number":["310030_182003\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_184747\/1"],"award-info":[{"award-number":["310030_184747\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012652","name":"ETH Z\u00fcrich Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012652","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dr. Horst B\u00f6hlke Foundation"},{"DOI":"10.13039\/501100013348","name":"Innosuisse - Schweizerische Agentur f\u00fcr Innovationsf\u00f6rderung","doi-asserted-by":"publisher","award":["120.421 IP-LS"],"award-info":[{"award-number":["120.421 IP-LS"]}],"id":[{"id":"10.13039\/501100013348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acute myeloid leukemia (AML) originates from the hematopoietic stem and progenitor cell compartment and is associated with an overall poor clinical outcome. T cell\u2013engaging bispecific antibodies (TCE), binding to a tumor-associated antigen and to CD3, redirect T cells to target antigen\u2013expressing cells in an MHC\/TCR-independent fashion. The development of TCEs for clinical application is facing several challenges. First, it is difficult to identify a tumor-selective, non\u2013MHC-presented tumor target, not expressed on the tissue of tumor origin, thus limiting specificity. Second, CD3-directed TCEs do not provide a second, T cell\u2013activating signal, such as the stimulation of CD28 or 41BB, thus possibly limiting T-cell efficacy. To address both aspects, we generated a CD33xCD28 IgG4-scFv2 with CD28 agonistic activity and tested it in combination with a previously by us reported CD117xCD3 TCE in AML. Combining these two bispecific antibodies significantly improved T cell\u2013mediated lysis of AML cell lines and primary AML samples by enhancing T-cell activation, proliferation, and cytokine release in vitro. Furthermore, the addition of CD33xCD28 IgG4-scFv2 showed faster time to cell attachment, increased lytic events, and improved specificity toward double-target\u2013expressing cells. In summary, the data indicate that combining costimulation via a second tumor-associated antigen to CD3-TCEs enhances T-cell lytic activity and simultaneously increases specificity against double-target\u2013expressing AML cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Current TCEs lack costimulatory signaling. The here-described CD33xCD28 IgG4-scFv2 delivers target-selective costimulation and enhances activation, proliferation, cytokine release, and cytotoxicity when used in combination with CD117xCD3 TCE in AML in vitro. Furthermore, the dual tumor-associated antigen targeting improves therapeutic specificity by preferentially eliminating CD117+CD33+ cells, possibly allowing improved bispecific antibody\u2013mediated AML therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0672","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:55:12Z","timestamp":1774889712000},"page":"946-960","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5058-576X","authenticated-orcid":false,"given":"Mara","family":"Hofstetter","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-2451","authenticated-orcid":false,"given":"Laura","family":"Volta","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0681-4265","authenticated-orcid":false,"given":"Christian","family":"Koch","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2594-4204","authenticated-orcid":false,"given":"Melanie Granados","family":"Rey","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0615-6608","authenticated-orcid":false,"given":"Monique","family":"Maurer","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3758-9711","authenticated-orcid":false,"given":"Nagihan","family":"G\u00f6n\u00fcll\u00fc","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-9988","authenticated-orcid":false,"given":"Christian","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1772-5912","authenticated-orcid":false,"given":"Celeste","family":"Gobbi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-4544","authenticated-orcid":false,"given":"Florin","family":"Schneiter","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a28rw58","id-type":"ROR","asserted-by":"publisher"}],"name":"ETH Zurich 3 Department of Biosystems Science and Engineering, , Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2409-944X","authenticated-orcid":false,"given":"Francesco","family":"Manfredi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-2159","authenticated-orcid":false,"given":"Chiara F.","family":"Magnani","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7080-0853","authenticated-orcid":false,"given":"Abdullah","family":"Elsayed","sequence":"additional","affiliation":[{"name":"4Philochem AG, Otelfingen, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9320-0252","authenticated-orcid":false,"given":"Timm","family":"Schroeder","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a28rw58","id-type":"ROR","asserted-by":"publisher"}],"name":"ETH Zurich 3 Department of Biosystems Science and Engineering, , Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-7370","authenticated-orcid":false,"given":"Dario","family":"Neri","sequence":"additional","affiliation":[{"name":"4Philochem AG, Otelfingen, Switzerland."},{"name":"5Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH Z\u00fcrich), Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-7931","authenticated-orcid":false,"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology and Hematology, University and University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland."},{"name":"2Comprehensive Cancer Center Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2026042708265209600_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"2026042708265209600_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"2026042708265209600_bib3","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.cell.2022.03.025","article-title":"Cancer stem cells: the adventurous journey from hematopoietic to leukemic stem cells","volume":"185","author":"Trumpp","year":"2022","journal-title":"Cell"},{"key":"2026042708265209600_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026042708265209600_bib5","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.3324\/haematol.2020.269134","article-title":"Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?","volume":"106","author":"McCurdy","year":"2021","journal-title":"Haematologica"},{"key":"2026042708265209600_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026042708265209600_bib7","volume-title":"Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML)","author":"National Cancer Institute","year":"2025"},{"key":"2026042708265209600_bib8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"2026042708265209600_bib9","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"2026042708265209600_bib10","volume-title":"Janeway\u2019s immunology: ninth international student edition","author":"Murphy","year":"2016"},{"key":"2026042708265209600_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2022.10.011","article-title":"From thymus to tissues and tumors: a review of T-cell biology","volume":"151","author":"Chopp","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026042708265209600_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1034\/j.1600-065X.2003.00009.x","article-title":"T cell anergy and costimulation","volume":"192","author":"Appleman","year":"2003","journal-title":"Immunol Rev"},{"key":"2026042708265209600_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"2026042708265209600_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"2026042708265209600_bib15","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"2026042708265209600_bib16","doi-asserted-by":"crossref","first-page":"ltab016","DOI":"10.1093\/immadv\/ltab016","article-title":"Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers","volume":"1","author":"Harrison","year":"2021","journal-title":"Immunother Adv"},{"key":"2026042708265209600_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026042708265209600_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026042708265209600_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"2026042708265209600_bib20","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"key":"2026042708265209600_bib21","doi-asserted-by":"crossref","first-page":"eabn1082","DOI":"10.1126\/scitranslmed.abn1082","article-title":"CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models","volume":"14","author":"Wei","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026042708265209600_bib22","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1182\/blood-2024-194830","article-title":"A CD38xCD28 costimulatory bispecific antibody demonstrates potent preclinical combinatorial activity with a BCMAxCD3 T cell-engager","volume":"144","author":"Olson","year":"2024","journal-title":"Blood"},{"key":"2026042708265209600_bib23","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2023-180890","article-title":"CD33-TIM3 dual CAR T cells: enhancing specificity while maintaining efficacy against AML","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"2026042708265209600_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1515\/hsz-2023-0329","article-title":"Better safe than sorry: dual targeting antibodies for cancer therapy","volume":"405","author":"Schoenfeld","year":"2024","journal-title":"Biol Chem"},{"key":"2026042708265209600_bib25","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","article-title":"Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells","volume":"38","author":"Volta","year":"2024","journal-title":"Leukemia"},{"key":"2026042708265209600_bib26","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"key":"2026042708265209600_bib27","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"key":"2026042708265209600_bib28","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"2026042708265209600_bib29","doi-asserted-by":"crossref","first-page":"e70055","DOI":"10.1002\/hem3.70055","article-title":"A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"8","author":"Volta","year":"2024","journal-title":"HemaSphere"},{"key":"2026042708265209600_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"2026042708265209600_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14712598.2025.2479014","article-title":"A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond","volume":"25","author":"Dykes","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"2026042708265209600_bib32","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"key":"2026042708265209600_bib33","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.3390\/cancers16213627","article-title":"Membrane antigen targeting in acute myeloid leukemia using antibodies or CAR-T cells","volume":"16","author":"Testa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026042708265209600_bib34","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"2026042708265209600_bib35","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood-2015-12-689356","article-title":"inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice","volume":"128","author":"Ellegast","year":"2016","journal-title":"Blood"},{"key":"2026042708265209600_bib36","doi-asserted-by":"crossref","first-page":"2220839","DOI":"10.1080\/19420862.2023.2220839","article-title":"Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties","volume":"15","author":"Elsayed","year":"2023","journal-title":"mAbs"},{"key":"2026042708265209600_bib37","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.4049\/jimmunol.148.4.1149","article-title":"Chimeric and humanized antibodies with specificity for the CD33 antigen","volume":"148","author":"Co","year":"1992","journal-title":"J Immunol"},{"key":"2026042708265209600_bib38","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1021\/acs.bioconjchem.0c00258","article-title":"Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing","volume":"31","author":"Pellegrino","year":"2020","journal-title":"Bioconjug Chem"},{"key":"2026042708265209600_bib39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nbt.3626","article-title":"Software tools for single-cell tracking and quantification of cellular and molecular properties","volume":"34","author":"Hilsenbeck","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026042708265209600_bib40","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nature18320","article-title":"Early myeloid lineage choice is not initiated by random PU.1 to GATA1 protein ratios","volume":"535","author":"Hoppe","year":"2016","journal-title":"Nature"},{"key":"2026042708265209600_bib41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-019-1531-6","article-title":"Asymmetric lysosome inheritance predicts activation of haematopoietic stem cells","volume":"573","author":"Loeffler","year":"2019","journal-title":"Nature"},{"key":"2026042708265209600_bib42","volume-title":"Antibody expression and production: the role of glycosylation in therapeutic antibodies","author":"Spearman","year":"2011"},{"key":"2026042708265209600_bib43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.copbio.2009.10.002","article-title":"Safety of biologics, lessons learnt from TGN1412","volume":"20","author":"Stebbings","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"2026042708265209600_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/1547691X.2012.711783","article-title":"After TGN1412: recent developments in cytokine release assays","volume":"10","author":"Stebbings","year":"2013","journal-title":"J Immunotoxicol"},{"key":"2026042708265209600_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/imcb.12646","article-title":"Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific Fc\u03b3RIIb binding and retention of super-agonist activity","volume":"101","author":"Chenoweth","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"2026042708265209600_bib46","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.4049\/jimmunol.1302461","article-title":"Cell contact\u2013dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response","volume":"192","author":"Bartholomaeus","year":"2014","journal-title":"J Immunol"},{"key":"2026042708265209600_bib47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1365-2141.2003.04085.x","article-title":"Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission","volume":"120","author":"Whiteway","year":"2003","journal-title":"Br J Haematol"},{"key":"2026042708265209600_bib48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41375-025-02566-x","article-title":"Immune checkpoints regulate acute myeloid leukemia stem cells","volume":"39","author":"Reinhardt","year":"2025","journal-title":"Leukemia"},{"key":"2026042708265209600_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cpt.1961","article-title":"Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology","volume":"108","author":"Betts","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026042708265209600_bib50","doi-asserted-by":"crossref","first-page":"e83659","DOI":"10.7554\/eLife.83659","article-title":"Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance","volume":"12","author":"Liu","year":"2023","journal-title":"eLife"},{"key":"2026042708265209600_bib51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/imr.13379","article-title":"Living in LALA land? Forty years of attenuating Fc effector functions","volume":"328","author":"Hale","year":"2024","journal-title":"Immunol Rev"},{"key":"2026042708265209600_bib52","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.leu.2400768","article-title":"Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)","volume":"11","author":"Matsuo","year":"1997","journal-title":"Leukemia"},{"key":"2026042708265209600_bib53","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"2026042708265209600_bib54","first-page":"33","article-title":"Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: a meta-analysis","volume":"13","author":"Al-Mansour","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"2026042708265209600_bib55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026042708265209600_bib56","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"2026042708265209600_bib57","doi-asserted-by":"crossref","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"2026042708265209600_bib58","doi-asserted-by":"crossref","first-page":"20201013","DOI":"10.1098\/rsif.2020.1013","article-title":"Quantifying the limits of CAR T-cell delivery in mice and men","volume":"18","author":"Brown","year":"2021","journal-title":"J R Soc Interf"},{"key":"2026042708265209600_bib59","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"2026042708265209600_bib60","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1182\/blood-2024-207398","article-title":"Efficacy of BCMA T-cell engagers (TCE) vs. chimeric antigen receptor T-cell therapy (CAR-T) following BCMA-directed therapies, relapsed\/refractory multiple myeloma: the chicken or the egg dilemma","volume":"144","author":"Snyder","year":"2024","journal-title":"Blood"},{"key":"2026042708265209600_bib61","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1007\/s00277-025-06524-6","article-title":"Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed\/refractory multiple myeloma: a meta-analysis of interventional and real-world studies","volume":"104","author":"Techaapornkun","year":"2025","journal-title":"Ann Hematol"},{"key":"2026042708265209600_bib62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ijc.35156","article-title":"The future of immunotherapy for diffuse large B-cell lymphoma","volume":"156","author":"Duell","year":"2025","journal-title":"Int J Cancer"},{"key":"2026042708265209600_bib63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","article-title":"Targeted immunotherapy: harnessing the immune system to battle multiple myeloma","volume":"10","author":"Xu","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026042708265209600_bib64","doi-asserted-by":"crossref","first-page":"e20231635","DOI":"10.1084\/jem.20231635","article-title":"Twisted: escape of epitope-edited healthy cells from immune attack","volume":"220","author":"Volta","year":"2023","journal-title":"J Exp Med"},{"key":"2026042708265209600_bib65","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/0975-1483.66810","article-title":"TGN1412: from discovery to disaster","volume":"2","author":"Attarwala","year":"2010","journal-title":"J Young Pharm"},{"key":"2026042708265209600_bib66","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"2026042708265209600_bib67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1535-7163.MCT-24-0327","article-title":"A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapies","volume":"24","author":"Moore","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2026042708265209600_bib68","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation","volume":"32","author":"Correnti","year":"2018","journal-title":"Leukemia"},{"key":"2026042708265209600_bib69","doi-asserted-by":"crossref","first-page":"eaba2325","DOI":"10.1126\/scitranslmed.aba2325","article-title":"Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy","volume":"12","author":"Waite","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026042708265209600_bib70","doi-asserted-by":"crossref","first-page":"719116","DOI":"10.3389\/fimmu.2021.719116","article-title":"Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models","volume":"12","author":"Warwas","year":"2021","journal-title":"Front Immunol"},{"key":"2026042708265209600_bib71","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2019-03-900894","article-title":"Selective CD117+ HSC exchange therapy","volume":"133","author":"Manz","year":"2019","journal-title":"Blood"},{"key":"2026042708265209600_bib72","doi-asserted-by":"crossref","first-page":"106732","DOI":"10.1016\/j.leukres.2021.106732","article-title":"Immunotherapy for Acute Myeloid Leukemia: allogeneic hematopoietic cell transplantation is here to stay","volume":"112","author":"Kaleka","year":"2022","journal-title":"Leuk Res"},{"issue":"Supplement 1","key":"2026042708265209600_bib73","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2023-185533","article-title":"Final results from phase 1 study of briquilimab, an anti-CD117 monoclonal antibody, in combination with low dose Irradiation and fludarabine conditioning, shows durable remissions in older adults with acute myeloid leukemia in complete remission and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation","volume":"142","author":"Gandhi","year":"2023","journal-title":"Blood"},{"key":"2026042708265209600_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-140422","article-title":"A single dose of a novel anti-human CD117-amanitin antibody drug conjugate (ADC) engineered for a short half-life provides dual conditioning and anti-leukemic activity and extends survival compared to standard of care in multiple preclinical models of Acute Myeloid Leukemia (AML)","volume":"136","author":"Lanieri","year":"2020","journal-title":"Blood"},{"key":"2026042708265209600_bib75","doi-asserted-by":"crossref","first-page":"eaaw7888","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026042708265209600_bib76","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"2026042708265209600_bib77","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","article-title":"Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell\u2013engaging antibody with potential for treatment of acute myelogenous leukemia","volume":"13","author":"Friedrich","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2026042708265209600_bib78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.273.5271.104","article-title":"T cell activation determined by T cell receptor number and tunable thresholds","volume":"273","author":"Viola","year":"1996","journal-title":"Science"},{"key":"2026042708265209600_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-065X.2009.00779.x","article-title":"Dynamic regulation of T-cell costimulation through TCR\u2013CD28 microclusters","volume":"229","author":"Yokosuka","year":"2009","journal-title":"Immunol Rev"},{"key":"2026042708265209600_bib80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2026042708265209600_bib81","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"2026042708265209600_bib82","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s13577-022-00670-z","article-title":"Activation-induced cell death in CAR-T cell therapy","volume":"35","author":"Huan","year":"2022","journal-title":"Hum Cell"},{"key":"2026042708265209600_bib83","doi-asserted-by":"crossref","first-page":"2033528","DOI":"10.1080\/2162402X.2022.2033528","article-title":"Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure","volume":"11","author":"Wachsmann","year":"2022","journal-title":"OncoImmunology"},{"key":"2026042708265209600_bib84","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/cancers14030497","article-title":"Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia","volume":"14","author":"Marvin-Peek","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0672\/3755608\/crc-25-0672.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/946\/3782249\/crc-25-0672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/946\/3782249\/crc-25-0672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:27:10Z","timestamp":1777292830000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/4\/946\/784419\/Enhancement-of-CD117-Targeted-Bispecific-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0672","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32699284","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699260","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699296","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699254","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699275","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699281","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699293","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699290","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699269","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699278","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699305","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699266","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699302","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8541934","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}